# Safety and Efficacy of AR/101 in Accelerating Re-epithelialization of Split Thickness Wounds

> **NCT02602184** · PHASE2 · UNKNOWN · sponsor: **Arava Bio Tech Ltd.** · enrollment: 18 (estimated)

## Conditions studied

- Wounds and Injuries

## Interventions

- **DRUG:** AR/101
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02602184
- **Lead sponsor:** Arava Bio Tech Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-11
- **Primary completion:** 2017-06
- **Final completion:** 2017-06
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2016-07-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02602184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02602184, "Safety and Efficacy of AR/101 in Accelerating Re-epithelialization of Split Thickness Wounds". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02602184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*